As a global leader in NASH and hepatology research, ICON delivers clinical expertise, experience, data and best practices to drive your program forward.
Our experts partner with sponsors, investigators, patients, and other collaborators to deliver strategic, data-driven solutions for NASH and hepatology studies.
ICON NASH and hepatology experience in the last five years:
Our clinical trial experience includes over 40 NASH studies, including five phase 3 NASH trials. In addition, we have supported clinical research in a range of indications, including:
- Fatty liver disease
- Hepatic encephalopathy
- Hepatobiliary disease or hepatic impairment, (non-specified)
- Liver disease (other)
- Liver impairment / failure
- Liver transplant
- Non-alcoholic steatohepatitis (NASH)
- Primary biliary cholangitis (PBC)
- Primary sclerosing cholangitis (PSC)
- Veno-occlusive disease
Our team is built of MDs, statisticians, regulatory scientists, DPDs, PMs, CTMs, and CRAs with hepatology-specific expertise who understand these complex patient populations and study protocols.
This experience, combined with our data capabilities and global infrastructure, provides clients with greater access to patients, advanced imaging support and overall advancement of hepatology research.
We are motivated in our daily work by the patients these treatments help, and we work to make clinical trial participation as convenient as possible for patients worldwide. We’ve crafted a superior patient journey, increasing access for potential participants, reducing the burden of participation, and enabling a truly patient-first experience throughout the entire development journey. Our protocols consider a patient’s daily life and standard of care and are free from unnecessary burdens and nuances. Building patient-focused studies not only helps patients who are enrolled but ultimately leads to faster approvals and widespread availability for all hepatology patients.
Webinar: Helping NASH study sites to succeed
How can pharma and biotech companies ensure that their NASH trial sites are set up for success and best supported to drive the development of new therapies? Register for the on-demand webinar.Register for the on-demand webinar